Good Wilson, XXXX. quarter cover Thank then of Officer, detailed and today our our to Dan thank is call. I'll you, for me today's full well Dan guidance. XXXX us. over as Stephanie. year the to call during turn on results afternoon all Chief our provide the performance XXXX XXXX for outlook joining Financial a and prepared joining annual as fourth My you remarks of business and financial review
channels. our in driven with of fourth quarter capped on XXXX volume significant year-over-year another volume customer we iRhythm, journey quarter across for achieved a class full accelerating during transformational of number by areas which revenue XXXX all our a year growth to of accomplishments become across best sustained every for year over XXXX demand XX% business. all The year
AT monitoring commercial commercial care value-based another for mobile drove continued long-term fourth teams an both Zio within telemetry. in entities, cardiac record the openings of momentum was in demand business national by continuous in Our our year strong enabled in account uplift and core new This quarter. a base
Zio celebrated And unveiled Zio XT smaller, monitor, XXXX registered is X newest our we particular marketplace. XXXX, patients product. performed legacy strength there disruption competitor our we its the Zio quarter was saw but compared very more and well specifically, continuous fourth superior at lighter, that long-term the for real-world monitoring continuous monitor a we breathable growth. HRX million to our to demonstrating performance in long-term data contribute Within that during in XXXX as for also this thinner throughout helped AT
has iRhythm the each today there tests prescribed of of number that our are cardiac which monitoring the U.S. by U.S. are performed as tests year, in being ambulatory market approximately historically described X.X million
are shift triage However, aging towards a and in of and health payer strategies of monitoring manage cardiovascular adoption capacity early increasing of clinician and burdens marked an the associated the to the broader stages to completely Including population. health disease an are that we patients home these the estimate the risk cardiac U.S. in patient-specific approximately complications that they there provider we have due XX to likely an placing factors. arrhythmia upon or care million with unaware system, that care present cost are
health seeing occurring. intervention, costs paradigm throughout physician that policing has stem the and to positioned is drive system. patient our TAM the the and detection diagnosis, will this reduce signs are ZIO reduce clinical already outcomes early believe is ideally been to within time we this the in care and upstream to early journey to moving business to hospitalizations, remain today Service care and patients these that further expansion access care We improve and shift, To win in primary paramount
large and through our from that We approach one down through top the integrated two as this national opportunity being have described we with accounts. to work large networks the delivery two-pronged: opening being in today,
networks full traction where we and utility EPs the efficiency care approaching primary physicians Zio tool. integrated of XXXX, During to care continued channels cardiologists, at are drive within large primary delivery
capacity qualified that place. take accounts be rule-out physicians these opening further for weeks ultimately, where X to to patients may X to be and seen as care months our versus what prescriptions the additional potential volumes primary the within by X see of time in have tool has in additional moving or upstream to to rule-in X decision clinical can to amplify specialists network, several to monitoring used referral to Zio for a We reduce systems to
EHR XXXX. that we primary have of XX% were prescribing accounts, pleased we integrated cross saw one very by enabled with we In our least of milestone independent the This networks and the physician do through electronic XXXX, further that in embedding business million delivery medical with now at is north at care record of Zio. accounts registrations Zio an to systems X large
commercial expanding our this Doubling with on positive. the we thus very integration partnership and down suite accounts EMR of been diagnostic with strategy, have via Aura's number has especially, reception far Epic the begun
time-to-value integration taken partnership workflow and allows still project improvement, to This major us operational has we've a early immediate turned at to on patients. in gains quicker be broad workflow and readiness IT and their heard commercial initiative from the as clinical our what spend low-effort a and have training to Epic into efficiency the time it launch in clinics part focus more more very IT staff of about used collaboration, that who these While initiatives. with been enthusiastic their suitability and
we been look to work able experience to thrilled have further partner, additional exceptional to We with an the or as customer throughout Epic forward be integrations XXXX. with improving and
national providers. incentives for significant a monitoring. iRhythm a TAM are cardiac to has top believe XXXX really several approaches a of accounts, was to and a the fourth drive also growth for open arrhythmias large and contribution we value-based where that account market we undiagnosed value-based product programs monitoring the during exists care within in validated this including factor with aligned started open line new guided payers added risk cost-efficient fit quarter first customer Through from innovative partner notable year strong ambulatory where this channel type, early
of enable monitored we arrhythmia programs using, we Zio least at This patient know and overarching representative downstream criteria that contribute lower of fall certain recently patients have hypothesis that over X support are arrhythmias sample opened, customer our from identification better inclusion with a is underlying when studies, scientific already had for identified. customers into that arrhythmias that outcomes. they patients and Within can great including to costs mSToPS, with of several the XX% one undiagnosed
Zio. have as expanding well patient be criteria partner new monitored Our to into recognizing proactively started their this customers one population with inclusion COPD the now with
fibrillation for we ambulatory as validation see on of broadened. ACC the are external the to stroke cardiac monitoring move Consensus recommends shown updated as monitoring of and explicitly or arrhythmias, primary monitoring monitoring for after the Expert U.S., Monitoring stroke in atrial now to use starting and monitoring monitoring fibrillation Holter In of continuous Zio a was Ambulatory XX long-term Early their for Stroke, Arhythmia Decision detection or was days and more superior as EPACS XXXX part active atrial option, origin. towards of post-stroke patients cases be of of of modality the in to cardiac recommendations Cardiac in detection Zio guideline trial. unknown included As Prolonged
rather more pool previously limited implantable were patients representing high-risk strategy, as of of change post- recommended patients. from a Also, a all than ILRs for significant recommended routine for use recorders a loop
or and years AFib older monitoring risk and of guidelines are recommendations patch-based cardiac In European older society guidelines recommended evolving XX appreciation population Society screening and those in Cardiology practice the for management the patients these XXXX management with reflective updated all an XX Europe, specifically highlight goals. their to include accomplish proactive monitoring and health for These additional factors. long-term and importance role of to for of for of updated the
advancements. many a of are now in this to conventional patient a on This other towards generated is for types that precision of advance starting apply approach be identified these better in to arrhythmias working our and populations, risk with acceptance shift by not technology criteria. of monitoring To further, we anticipation targeted team evidence fibrillation atrial AI would be just factor-based market
talk overlapping clinical an heard quite of us these sleep where the and abundance apnea pointing is in past to obstructive comorbidities literature of You've failure, about bit arrhythmias. disease a there heart the
utilization X data X sessions combined length as stay heart disease. with serious November, conditions the relative early and demonstrating and by cohort. arrhythmia as were non-arrhythmia patients. suggested disease arrhythmias, shared example arrhythmia has often compared scientific significant and outcomes monitoring great like room detection And to significantly for in Everstone at these related for real-world devices than acute type failure patient diabetes, detection rate X those emergency like data Analysis often Association's more benefits potential with COPD, arrhythmia without twice than conducted stroke this Heart care more showed the of reduce was combined These hospitalized, coronary non-arrhythmia the chronic arrhythmia and economic the to past cohort of of claims patients twice patients overlooked to populations. kidney that the that by that this a help hospitalized to arrhythmia increased and patients days was early artery the of Another XXXX prevent that the American of of cost health
event AI potential increased for to visits, ER of that to has ahead taking and believe meaningfully at leading monitoring, place, events caring patients of of hospitalizations can risk catastrophic precision-based of catastrophic with occurred. We approach are who find cost the high the we after these patients proactive cardiac reduce to arrhythmias a these cost
quarter to third positively Services disrupt in and we ZIO OUS our ZIO business, in with opening believe markets the Europe, Outside bring our these to and our millions global our monitoring the U.K. more the and globally. of XXXX, with drove as continue evidence reimbursement ZIO We private introduction additional commercial begin billable with expand paradigm practice during clinical core navigate launch potentially U.S. Also XXXX made improved record Spain. team we to registrations contracts dynamics will the of Switzerland In through continue patients NHS. outcomes. in reach Netherlands, Services the to allow Austria, progress the countries we to Service
first deliver PMDA hand this past to from support Japan, the received Zio Welfare, towards Rhythm and artificial the the and monitoring product a Zio. months being regulatory for Labor Society, with In decision market few approval past of regulatory and Heart approval With we in MHLW, or we've Japan Industry in Japan working monitor with with arrhythmia our September service reimbursement Health, Japanese utilizing intelligence. at the the partners Japanese for over access been Zio
and back commercially soon hear excited the are market to regarding expect in device launch to second-largest We world. the medical in the decision
where but insights, signs, health our clinical care iRhythm's and health innovative platform influencing is about disease technology vital multiple heading. generating future enabling, underpins management ultimately, across today additional to foundational think is states population service adding how we
multiple As are in-licensing multi-parameter monitoring this we that technology believe off by chest. announced in enable vital approaching we hardware iterations modalities of may the XXXX, signs the sensing with future long-term strategically containing we goal
where for the and functional advantage leadership adding We as us multi-sensing To provide the reimbursement. rigor variances, to continue future are a modalities way us, to and of take these adjacent required we significant maturation apnea company. opportunities enable the solution driven additional capabilities, diverse exciting new factors of past over ahead years, we within patch operate other indications technological believe diagnosis diagnostics winning increasing additional are service of and into have form couple that transformation as vitals may such sleep Zio our for
automation our next-generation XXXX, cost. set Zio the and in initial established stage of platform yielding the growth marking phase significant launched monitor in substantial intended XXXX, With to corporate as for hardware future manufacturing milestone plans also innovation the our we while a
Also effectiveness executed And layers were $XX our in during global aspirations savings while corporate our operations. last established infrastructure and worldwide, to the of patients to global XXXX, leveraging than XX millions global and we we reduce support enabling in our that months aim million organization center, in enacted operational globalize with in activities the with efficiency of we more XXXX. to business more serve services over continue have workforce the increasing the delivering around-the-clock management
improved corresponding XX% XXX the IPR&D and fourth benefit year. to and of of remain in excluding margin for have in resulted basis maturing quarter committed XXXX north for have stakeholders. our the points generated We further to of adjusted our within have EBITDA of company the all efforts by of cumulative at financial charges gross the margin, leverage beginning we financial year transformation business improvement from as driving acquired the additional the to profile XX% These a
time want will tracking Lastly, while regulatory we of company throughout we and remain this committed observations. driving To business, are lines warning in opportunities commercial are us very have our to against we FDA's towards with respect to and remediation the are to end, and excited I priority we FDA the for matters that letter progress activities our our make quality that to XXXX. everyone the well continue and significant our XXX remind ahead #X that compliance
track Also committed we to compliance XXXX. expect, has we on recall these additional they efforts to year-end currently what and are signaled complete above FDA and that going by beyond the
a will their complete communicated we best in to and are ensuring past, have are FDA's committed the class are necessary quality to resources to in we observations As the from we we that remedied allocate ensure the that satisfaction. perspective,
I'll Dan our now performance. that, With turn call to discuss financial over to the recent
